However, these benefits are unlikely to be solely explained by improved blood glucose control, as other antidiabetic medications have not shown similar protective effects on the damaged heart, and SGLT2 inhibitors have also demonstrated cardioprotective effects in non-diabetic heart failure animals or patients (Yurista et al., 2019; Escobar et al., 2023). The gene discussed is SLC5A2; the disease is heart failure.